Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q2 2025 Earnings Presentation
16 slides from Bactiguard Holding Ab's earnings presentation, Jul 15, 2025
Slide 1: Q2 2025 presentation
Q2 2025 presentation Tuesday 15 July 2025 Christine Lind, CEO Patrick Bach, CFO
Slide 2: Q2 2025 key figures and highlights
Q2 2025 key figures and highlights Positive EBITDA momentum carried forward in Q2 Key figures for Q2 2025 (Q2 2024) Highlights • Fifth consecutive quarter with positive Revenues 52.1 (60.9) MSEK EBITDA • Strong momentum in BD partnership EBITDA 4.4 (1.2) MSEK despite delays in market approvals Net l
Slide 3: Focus areas and priorities
Focus areas and priorities “infection prevention is our mission” R&D Wound License Medical Management partnerships portfolio Regulatory Advance current and develop Invest in Grow profitably and new partnerships key competencies expand into new markets 3
Slide 4: Focus therapeutic areas
Focus therapeutic areas Areas with high unmet medical needs Orthopedics1-3 Cardiology 4,5 Neurology 6,7 Urology 8 Vascular access 9 Hip Implants Deep Brain Stimulator Central Venous Catheter Application areas Ventricular Assisted Device Foley Catheter Knee Implants Vagus Nerve Stimulator Peripherall
Slide 5: Partnership snapshot Q2 2025
Partnership snapshot Q2 2025 Exclusivity partnerships and License partnerships announced with partner name Material transfer Application development Exclusivity partnership License partnership agreement partnership Orthopedics Cardiology Neurology Urology Vascular access Other 5
Slide 6: BD partnership update
BD partnership update Strong momentum in partnership • Collaboration spanning entire value chain – from technology licensing to go-to-market strategies • BD US website updated with comprehensive section on Bactiguard-coated Foley catheters • Bactiguard-coated Foley catheters (latex and silicone) reg
Slide 7: Zimmer Biomet partnership update
Zimmer Biomet partnership update Commercialization of ZNN Bactiguard across Europe continues • Commercialization of ZNN Bactiguard across Europe and regulatory processes (MDR for Europe) • International Consensus Meeting on Infection (Istanbul, May) – ZNN Bactiguard part of offering on infection pre
Slide 8: Wound Management by Bactiguard
Wound Management by Bactiguard Preventing infections through effective, biocompatible solutions to improve wound healing • Hydrocyn aqua delivered strong growth – represents majority of Wound Management revenues • Over the first six months of 2025, Wound Management business delivered 21 percent grow
Slide 9: Total revenue decreased 14% overall in Q2 and 10% net of currency effects
Total revenue decreased 14% overall in Q2 and 10% net of currency effects driven by both License and WM Revenue development MSEK Other revenues BIP portfolio Wound Management portfolio Total license revenue Second quarter (Apr-Jun) Year to date (Jan-Jun) Full year RTM 261,9 257,0 20,2 19,4 16,0 6,0
Slide 10: Total license revenues decreased 10% overall in Q2 but were flat net of currency
Total license revenues decreased 10% overall in Q2 but were flat net of currency, while YTD still positive License revenue development MSEK Application development partners Exclusivity partners License partners Second quarter (Apr-Jun) Year to date (Jan-Jun) Full year RTM 164,7 165,1 7,7 1,5 2,5 1,5
Slide 11: Total operating costs (OPEX) further decreased in Q2 by 14%
Total operating costs (OPEX) further decreased in Q2 by 14% with savings in both external and personnel costs Total operating costs (OPEX) development MSEK Personnel costs Other external expenses Other operating expenses Second quarter (Apr-Jun) Year to date (Jan-Jun) Full year RTM 207,9 194,5 111,5
Slide 12: Positive EBITDA of SEK 4.4 million in Q2
Positive EBITDA of SEK 4.4 million in Q2 with EBITDA of SEK 32.1 million in RTM EBITDA development MSEK EBITDA Second quarter (Apr-Jun) Year to date (Jan-Jun) Full year RTM 32.1 +14.1 18.0 13.8 +3.2 4.4 1.2 -0.3 2024 2025 2024 2025 2024 2024/25 12 Source: Bactiguard Holding AB, Interim report Q1 202
Slide 13: Total cash flow flat for Q2 with positive operating cash flow
Total cash flow flat for Q2 with positive cash flow from operating activities of SEK 1.7 million Cash flow for the period and total cash development MSEK 1,7 -1,8 46,8 -0,4 -0,3 46,1 Cash end Cash flow Cash flow Cash flow Exchange Cash end of Q1 2025 from operating from investing from financing diff
Slide 14: Q2 2025 key takeaways
Q2 2025 key takeaways Positive EBITDA momentum carried forward in Q2 • Fifth consecutive quarter with positive EBITDA • Strong momentum in BD partnership – albeit delays in market registrations • Zimmer Biomet continues ZNN Bactiguard commercialization across Europe • Making progress in business dev
Slide 15: Questions & Answers
Questions & Answers Q2 2025 presentation Christine Lind Patrick Bach CEO CFO
Slide 16: Q&A to champion a healthier world by preventing infections
Q&A to champion a healthier world by preventing infections